These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 10346718)

  • 21. Stoning a dead bird: advertising limits on approved new drugs.
    Strobos J
    Food Drug Law J; 1995; 50(4):533-51. PubMed ID: 10343018
    [No Abstract]   [Full Text] [Related]  

  • 22. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
    Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Content and format of labeling for human prescription drugs; pregnancy labeling; public hearing--FDA. Notice of public hearing; request for comments.
    Fed Regist; 1997 Jul; 62(147):41061-3. PubMed ID: 10169832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Pharmaceutical Access and Prudent Purchasing Act of 1990: Federal law shifts the duty to warn from the physician to the pharmacist.
    Holleran MJ
    Spec Law Dig Health Care (Mon); 1993 Dec; (178):9-30. PubMed ID: 10131324
    [No Abstract]   [Full Text] [Related]  

  • 25. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 26. Importing prescription drugs: risky business.
    Hassel L; Arzuaga P
    Empl Benefits J; 2003 Dec; 28(4):83-6. PubMed ID: 14712740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AHI perspectives: flexible drug labeling and its impact on the drug development process. Liability issues.
    Thomas JW
    J Am Vet Med Assoc; 1995 Oct; 207(7):899-900; discussion 902-4. PubMed ID: 7559021
    [No Abstract]   [Full Text] [Related]  

  • 28. The black box warning.
    Abourjaily HM; Rosenberg M
    J Mass Dent Soc; 2002; 51(3):54-6. PubMed ID: 12380043
    [No Abstract]   [Full Text] [Related]  

  • 29. Proposed legislation--its impact on drug information processing.
    Cleveland CB; Adams J
    Drug Inf J; 1978; 12(3):181-4. PubMed ID: 10239117
    [No Abstract]   [Full Text] [Related]  

  • 30. Patient package inserts: the proper prescription?
    Rowe HM
    Food Drug Law J; 1995; 50(1):95-124. PubMed ID: 10342988
    [No Abstract]   [Full Text] [Related]  

  • 31. Pediculicide drug products for over-the-counter human use; amendment of final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(250):75414-8. PubMed ID: 14986677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S; Roberts R
    J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enterprise liability for bad outcomes from drug therapy: the doctor, the hospital, the pharmacy, and the drug firm.
    Furrow BR
    Spec Law Dig Health Care Law; 1998 Apr; (229):9-69. PubMed ID: 10178162
    [No Abstract]   [Full Text] [Related]  

  • 34. Bringing greater transparency to "black box" warnings.
    Buckley NA; Rossi S
    Clin Toxicol (Phila); 2011 Jul; 49(6):448-51. PubMed ID: 21824055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA off-track on off-label drug promotion.
    Lancet; 2007 Dec; 370(9604):1976. PubMed ID: 18083382
    [No Abstract]   [Full Text] [Related]  

  • 36. The regulatory role of the United States Food and Drug Administration.
    Ortiz EM
    J Reprod Med; 1972 Apr; 8(4):205-6. PubMed ID: 5029971
    [No Abstract]   [Full Text] [Related]  

  • 37. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 38. The use of droperidol before and after the Food and Drug Administration black box warning: a survey of the members of the Society of Ambulatory Anesthesia.
    Habib AS; Gan TJ
    J Clin Anesth; 2008 Feb; 20(1):35-9. PubMed ID: 18346607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT; Barash PG
    Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Point of law: what are the legal implications of prescribing and administering FDA-approved drugs in nonapproved ways?
    Kaunitz AM
    Hosp Med Staff; 1982 Feb; 11(2):15-8. PubMed ID: 10254209
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.